LA Private

Uncategorized

WAM Global (WGB) Reports Strong FY25 Results, Boosts Final Dividend

WAM Global Limited (WGB), a listed investment company providing investors with exposure to an actively managed diversified portfolio of high quality undervalued international growth companies and exposure to market mispricing opportunities, has announced its preliminary final report for the year ended 30 June 2025. The report showcases a substantial increase in revenue and profit compared […]

WAM Global (WGB) Reports Strong FY25 Results, Boosts Final Dividend Read More »

FDA Extends Review Timeline for Neurizon’s NUZ-001 Clinical Hold Response

Neurizon Therapeutics Limited (ASX: NUZ), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline for its Clinical Hold Complete Response (CHCR) to the Investigational New Drug (IND) application for NUZ-001. NUZ-001 is the company’s lead investigational therapy

FDA Extends Review Timeline for Neurizon’s NUZ-001 Clinical Hold Response Read More »

Ryder Capital (RDY) Announces Strong FY25 Results, Final Dividend

Ryder Capital Limited (RDY), an ASX-listed investment firm that invests in a concentrated portfolio of ASX-listed small to mid-capitalisation securities, bonds and cash, has announced its preliminary final report for the year ended 30 June 2025. The company reported a substantial increase in revenue from ordinary activities, reaching $30,953,879, up from the previous corresponding period.

Ryder Capital (RDY) Announces Strong FY25 Results, Final Dividend Read More »

Ryder Capital Announces Increased Dividend and Strong FY25 Performance

Ryder Capital Limited (ASX:RYD), a Sydney-based boutique fund manager specialising in small to mid-cap Australasian equities with a high conviction value driven investment strategy, has announced a 10% increase in its final dividend for FY25, rising to 5.5 cents per share fully franked. This decision follows a year of robust financial performance, marked by a

Ryder Capital Announces Increased Dividend and Strong FY25 Performance Read More »

FDA Extends Review Timeline for Neurizon’s NUZ-001 Clinical Hold Response

Neurizon Therapeutics Limited (ASX: NUZ), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline for its Clinical Hold Complete Response (CHCR) to the Investigational New Drug (IND) application for NUZ-001. NUZ-001 is the company’s lead investigational therapy

FDA Extends Review Timeline for Neurizon’s NUZ-001 Clinical Hold Response Read More »

Waller Emerges as Fed Chair Contender

Federal Reserve governor Christopher Waller has surfaced as a leading candidate to become the central bank’s chairman. According to sources familiar with the matter, President Donald Trump’s advisers are considering Waller as a replacement for the current chairman, Jerome Powell. Waller’s qualifications and policy perspectives have reportedly resonated with the President’s team as they evaluate

Waller Emerges as Fed Chair Contender Read More »

Schroders Warns of US Economic Slowdown

Schroders Australia is cautioning investors that markets are underestimating the potential for a sharp economic slowdown in the United States. Kellie Wood, the head of fixed income at Schroders Australia, voiced concerns that current market valuations do not adequately reflect weakening demand and other concerning economic indicators. Schroders is a global asset management firm offering

Schroders Warns of US Economic Slowdown Read More »